Related Experiment Video
Updated: Mar 21, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients
Alexis Régent1, Serge Redeker1, Alban Deroux1
1From the Université Paris-Descartes; APHP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne, Paris; Service de médecine interne, Centre hospitalier d'Abbeville, Abbeville; Service de médecine interne, Université Grenoble Alpes, Centre Hospitalier Universitaire (CHU) de Grenoble, Grenoble; Service de médecine interne, Centre Hospitalier Général de Mulhouse, Mulhouse; Service de médecine interne, CHU de Limoges, Limoges; Department of Rheumatology, Hôpital Cochin, APHP; INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris; Service de médecine interne, Hôpital Avicenne, Bobigny; Service de médecine interne, Hôpital Hôtel-Dieu, Nantes; Service de rhumatologie, CHU de Clermont-Ferrand, Clermont Ferrand; Service de médecine interne et médecine polyvalente, Hôpital de Saint Quentin, Saint Quentin; Service de médecine interne, CH de Dax, Dax; Service de médecine interne, Hôpital Claude Huriez, Lille; Centre d'Investigation Clinique Biothérapie INSERM CIC-1431, FHU INCREASE, Service de rhumatologie, Centre Hospitalier Régional Universitaire (CHRU), Besançon, France.A. Régent, MD, PhD, Université Paris-Descartes; APHP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne; S. Redeker, MD, Service de médecine interne, Centre hospitalier d'Abbeville; A. Deroux, MD, Service de médecine interne, Université Grenoble Alpes, CHU de Grenoble; P. Kieffer, MD, Service de médecine interne, Centre Hospitalier Général de Mulhouse; K.H. Ly, MD, PhD, Service de médecine interne, CHU de Limoges; M. Dougados, MD, PhD, Université Paris-Descartes, Department of Rheumatology, APHP, Hôpital Cochin, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité; E. Liozon, MD, Service de médecine interne, CHU de Limoges; C. Larroche, MD, Service de médecine interne, Hôpital Avicenne;
Objective:
To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).
Methods:
A retrospective multicenter study that included 34 patients receiving TCZ for GCA.
Results:
TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.
Conclusion:
TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies